Literature DB >> 7840337

Mesenteric vascular responses to vasopressin during development of DOCA-salt hypertension in male and female rats.

J N Stallone1.   

Abstract

Deoxycorticosterone acetate (DOCA)-salt hypertension develops to a greater extent in male (M) than in female (F) rats. To determine the role of the vasculature, reactivity to arginine vasopressin (AVP) and prostanoid output were examined in the isolated perfused mesenteric vasculature of hypertensive (HT) and normotensive-control (NTC) M and F rats after acute (1-wk) and chronic (4-wk) DOCA-salt treatment. Systolic blood pressure was significantly higher in M than in F HT rats (187 +/- 3 vs. 151 +/- 3 mmHg after 4 wk; P < 0.02). After acute treatment, vascular reactivity to AVP (maximal perfusion pressure) in HT was elevated in M (181 +/- 18 mmHg; P < 0.02) but not in F (135 +/- 6 mmHg) compared with NTC (90 +/- 6 mmHg, M vs. 119 +/- 5 mmHg, F). After chronic treatment, vascular reactivity to AVP in HT was elevated in both sexes (P < 0.02), although more in F (175 +/- 13 mmHg) than in M (141 +/- 11 mmHg). In contrast, vascular responsiveness to phenylephrine did not differ significantly between M and F NTC or HT preparations after either acute or chronic treatment. Sex differences in basal and AVP-induced 6-ketoprostaglandin (6-keto-PG) F1 alpha and PGE2 output by HT and NTC vasculature were reciprocal to sex differences in the vasoconstriction responses to AVP. After acute treatment, AVP-stimulated 6-keto-PGF1 alpha output by HT was elevated slightly in F (33.6 +/- 1.7 ng/3 min; P < or = 0.02) but not in M (49.9 +/- 4.3 ng/3 min) compared with NTC (23.5 +/- 2.6 ng/3 min, F vs. 34.7 +/- 4.9 ng/3 min, M). After chronic treatment, output by HT was enhanced in both sexes (P < or = to 0.02), although more in M (109 +/- 15.4 ng/3 min) than in F (68 +/- 6.6 ng/3 min)> These findings suggest that sex differences in the relative balance between AVP-induced vasoconstriction and vasodilatory prostanoid release may contribute to male-female differences in mesenteric vascular reactivity to AVP in NT and that disturbances in this balance may be responsible, at least in part, for the sex- and time-dependent changes in reactivity to AVP observed during the development of DOCA-salt hypertension.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7840337     DOI: 10.1152/ajpregu.1995.268.1.R40

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  4 in total

1.  Extracellular signal-regulated kinase 1/2 activation, via downregulation of mitogen-activated protein kinase phosphatase 1, mediates sex differences in desoxycorticosterone acetate-salt hypertension vascular reactivity.

Authors:  Fernanda R Giachini; Jennifer C Sullivan; Victor V Lima; Fernando S Carneiro; Zuleica B Fortes; David M Pollock; Maria Helena C Carvalho; R Clinton Webb; Rita C Tostes
Journal:  Hypertension       Date:  2009-11-09       Impact factor: 10.190

2.  The chemerin knockout rat reveals chemerin dependence in female, but not male, experimental hypertension.

Authors:  Stephanie W Watts; Emma S Darios; Adam E Mullick; Hannah Garver; Thomas L Saunders; Elizabeth D Hughes; Wanda E Filipiak; Michael G Zeidler; Nichole McMullen; Christopher J Sinal; Ramya K Kumar; David J Ferland; Gregory D Fink
Journal:  FASEB J       Date:  2018-06-15       Impact factor: 5.191

3.  Greater T Regulatory Cells in Females Attenuate DOCA-Salt-Induced Increases in Blood Pressure Versus Males.

Authors:  Kasey M Belanger; G Ryan Crislip; Ellen E Gillis; Mahmoud Abdelbary; Jacqueline B Musall; Riyaz Mohamed; Babak Baban; Ahmed Elmarakby; Michael W Brands; Jennifer C Sullivan
Journal:  Hypertension       Date:  2020-04-27       Impact factor: 10.190

4.  Waveform Analysis of the Brachial-ankle Pulse Wave Velocity in Hemiplegic Stroke Patients and Healthy Volunteers: A Pilot Study.

Authors:  Ju-Hyun Kim; Mee-Young Kim; Jeong-Uk Lee; Lim-Kyu Lee; Seung-Min Yang; Hye-Joo Jeon; Won-Deok Lee; Ji-Woong Noh; Taek-Yong Kwak; Tae-Hyun Lee; Jin-Hwan Kim; Yong Huh; Junghwan Kim
Journal:  J Phys Ther Sci       Date:  2014-04-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.